New research supports 'biological passport' for growth hormone doping in sport (AlphaGalileo, 1 June 2010)

Slim teenager transforms into 6ft 8ins giant after rare hormone disorder sees her weight QUADRUPLE (Daily Mail, 31 May 2010)

Amgen, Glaxo bone drug wins EU OK, shares rise (Reuters, 28 May 2010)

28 May 2010

Denosumab, a monoclonal antibody marketed under the name of 'Prolia' has been approved by the European Commission for the treatment of osteoporosis in postmeonpausal women, and to treat bone loss resulting from advanced hormonal prostate cancer treatment.

Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Most read